| 001 | 162787 | ||
| 005 | 20240320115515.0 | ||
| 024 | 7 | _ | |a pmc:PMC8739306 |2 pmc |
| 024 | 7 | _ | |a 10.1007/s00415-021-10866-2 |2 doi |
| 024 | 7 | _ | |a pmid:34718884 |2 pmid |
| 024 | 7 | _ | |a 0012-1037 |2 ISSN |
| 024 | 7 | _ | |a 0340-5354 |2 ISSN |
| 024 | 7 | _ | |a 0939-1517 |2 ISSN |
| 024 | 7 | _ | |a 1432-1459 |2 ISSN |
| 024 | 7 | _ | |a 1619-800X |2 ISSN |
| 024 | 7 | _ | |a 0367-004x |2 ISSN |
| 024 | 7 | _ | |a 0367-004X |2 ISSN |
| 037 | _ | _ | |a DZNE-2021-01442 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Tütüncü, Serdar |b 0 |
| 245 | _ | _ | |a Off-label-dosing of non-vitamin K-dependent oral antagonists in AF patients before and after stroke: results of the prospective multicenter Berlin Atrial Fibrillation Registry. |
| 260 | _ | _ | |a Berlin |c 2022 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655200190_926 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a ISSN 1432-1459 not unique: **2 hits**. (CC BY) |
| 520 | _ | _ | |a We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke.The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke.At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01].At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge.NCT02306824. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 542 | _ | _ | |i 2021-10-31 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 542 | _ | _ | |i 2021-10-31 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Atrial fibrillation |2 Other |
| 650 | _ | 7 | |a Ischemic stroke |2 Other |
| 650 | _ | 7 | |a NOAC |2 Other |
| 650 | _ | 7 | |a Under-dosing |2 Other |
| 650 | _ | 2 | |a Administration, Oral |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Anticoagulants: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: complications |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Berlin |2 MeSH |
| 650 | _ | 2 | |a Brain Ischemia: complications |2 MeSH |
| 650 | _ | 2 | |a Brain Ischemia: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Off-Label Use |2 MeSH |
| 650 | _ | 2 | |a Prospective Studies |2 MeSH |
| 650 | _ | 2 | |a Registries |2 MeSH |
| 650 | _ | 2 | |a Stroke: complications |2 MeSH |
| 650 | _ | 2 | |a Stroke: drug therapy |2 MeSH |
| 700 | 1 | _ | |a Olma, Manuel |b 1 |
| 700 | 1 | _ | |a Kunze, Claudia |b 2 |
| 700 | 1 | _ | |a Dietzel, Joanna |b 3 |
| 700 | 1 | _ | |a Schurig, Johannes |b 4 |
| 700 | 1 | _ | |a Fiessler, Cornelia |b 5 |
| 700 | 1 | _ | |a Malsch, Carolin |b 6 |
| 700 | 1 | _ | |a Haas, Tobias Eberhard |b 7 |
| 700 | 1 | _ | |a Dimitrijeski, Boris |b 8 |
| 700 | 1 | _ | |a Doehner, Wolfram |b 9 |
| 700 | 1 | _ | |a Hagemann, Georg |b 10 |
| 700 | 1 | _ | |a Hamilton, Frank |b 11 |
| 700 | 1 | _ | |a Honermann, Martin |b 12 |
| 700 | 1 | _ | |a Jungehulsing, Gerhard Jan |b 13 |
| 700 | 1 | _ | |a Kauert, Andreas |b 14 |
| 700 | 1 | _ | |a Koennecke, Hans-Christian |b 15 |
| 700 | 1 | _ | |a Mackert, Bruno-Marcel |b 16 |
| 700 | 1 | _ | |a Nabavi, Darius |b 17 |
| 700 | 1 | _ | |a Nolte, Christian H |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Reis, Joschua Mirko |b 19 |
| 700 | 1 | _ | |a Schmehl, Ingo |b 20 |
| 700 | 1 | _ | |a Sparenberg, Paul |b 21 |
| 700 | 1 | _ | |a Stingele, Robert |b 22 |
| 700 | 1 | _ | |a Völzke, Enrico |b 23 |
| 700 | 1 | _ | |a Waldschmidt, Carolin |b 24 |
| 700 | 1 | _ | |a Zeise-Wehry, Daniel |b 25 |
| 700 | 1 | _ | |a Heuschmann, Peter U |b 26 |
| 700 | 1 | _ | |a Endres, Matthias |0 P:(DE-2719)2811033 |b 27 |u dzne |
| 700 | 1 | _ | |a Haeusler, Karl Georg |b 28 |
| 773 | 1 | 8 | |a 10.1007/s00415-021-10866-2 |b Springer Science and Business Media LLC |d 2021-10-31 |n 1 |p 470-480 |3 journal-article |2 Crossref |t Journal of Neurology |v 269 |y 2021 |x 0340-5354 |
| 773 | _ | _ | |a 10.1007/s00415-021-10866-2 |0 PERI:(DE-600)1421299-7 |n 1 |p 470-480 |t Journal of neurology |v 269 |y 2021 |x 0340-5354 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/162787/files/DZNE-2021-01442.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/162787/files/DZNE-2021-01442.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:162787 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 27 |6 P:(DE-2719)2811033 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEUROL : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NEUROL : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-12 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Coordinator of Clinical Research |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |a 10.1056/NEJMoa0905561 |9 -- missing cx lookup -- |1 SJ Connolly |p 1139 - |2 Crossref |u Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151 |t N Engl J Med |v 361 |y 2009 |
| 999 | C | 5 | |a 10.1056/NEJMoa1009638 |9 -- missing cx lookup -- |1 MR Patel |p 883 - |2 Crossref |u Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891 |t N Engl J Med |v 365 |y 2011 |
| 999 | C | 5 | |a 10.1056/NEJMoa1107039 |9 -- missing cx lookup -- |1 CB Granger |p 981 - |2 Crossref |u Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992 |t N Engl J Med |v 365 |y 2011 |
| 999 | C | 5 | |a 10.1056/NEJMoa1310907 |9 -- missing cx lookup -- |1 RP Giugliano |p 2093 - |2 Crossref |u Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104 |t N Engl J Med |v 369 |y 2013 |
| 999 | C | 5 | |a 10.1001/jamaneurol.2019.2099 |9 -- missing cx lookup -- |1 Y Xian |p 1192 - |2 Crossref |u Xian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL et al (2019) Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol 76(10):1192–1202 |t JAMA Neurol |v 76 |y 2019 |
| 999 | C | 5 | |2 Crossref |u Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE et al (2020) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J |
| 999 | C | 5 | |a 10.1161/CIR.0000000000000665 |9 -- missing cx lookup -- |1 CT January |p e125 - |2 Crossref |u January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 140(2):e125–e151 |t Circulation |v 140 |y 2019 |
| 999 | C | 5 | |2 Crossref |u (AWMF) AdWMF: S3-Leitlinie Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke |
| 999 | C | 5 | |a 10.1093/europace/euz199 |9 -- missing cx lookup -- |1 KG Haeusler |p 1621 - |2 Crossref |u Haeusler KG, Tütüncü S, Kunze C, Schurig J, Malsch C, Harder J, Wiedmann S, Dimitrijeski B, Ebinger M, Hagemann G et al (2019) Oral anticoagulation in patients with atrial fibrillation and acute ischaemic stroke: design and baseline data of the prospective multicentre Berlin Atrial Fibrillation Registry. Europace 21(11):1621–1632 |t Europace |v 21 |y 2019 |
| 999 | C | 5 | |a 10.1177/1747493017733928 |9 -- missing cx lookup -- |1 C Tanislav |p 308 - |2 Crossref |u Tanislav C, Allendörfer J, Pfeilschifter W, Fuest S, Stein M, Meyer M, Reuter I, Kaps M, Misselwitz B (2018) One decade of oral anticoagulation in stroke patients: results from a large country-wide hospital-based registry. Int J Stroke 13(3):308–312 |t Int J Stroke |v 13 |y 2018 |
| 999 | C | 5 | |a 10.1007/s00392-019-01437-7 |9 -- missing cx lookup -- |1 SH Hohnloser |p 1042 - |2 Crossref |u Hohnloser SH, Basic E, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol 108(9):1042–1052 |t Clin Res Cardiol |v 108 |y 2019 |
| 999 | C | 5 | |a 10.1016/j.ahj.2017.08.011 |9 -- missing cx lookup -- |1 BA Steinberg |p 132 - |2 Crossref |u Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S et al (2017) International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 194:132–140 |t Am Heart J |v 194 |y 2017 |
| 999 | C | 5 | |a 10.1093/eurheartj/ehy136 |9 -- missing cx lookup -- |1 J Steffel |p 1330 - |2 Crossref |u Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393 |t Eur Heart J |v 39 |y 2018 |
| 999 | C | 5 | |a 10.1016/j.jacc.2016.09.966 |9 -- missing cx lookup -- |1 BA Steinberg |p 2597 - |2 Crossref |u Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J et al (2016) Off-label dosing of non-vitamin k antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J Am Coll Cardiol 68(24):2597–2604 |t J Am Coll Cardiol |v 68 |y 2016 |
| 999 | C | 5 | |a 10.1016/j.tcm.2017.06.012 |9 -- missing cx lookup -- |1 BA Steinberg |p 567 - |2 Crossref |u Steinberg BA, Washam JB (2017) Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends Cardiovasc Med 27(8):567–572 |t Trends Cardiovasc Med |v 27 |y 2017 |
| 999 | C | 5 | |a 10.1186/s40780-020-0157-z |9 -- missing cx lookup -- |1 M Miyazaki |p 2 - |2 Crossref |u Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, Tokura K, Jimi S, Okamura K, Adachi S et al (2020) Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci 6:2 |t J Pharm Health Care Sci |v 6 |y 2020 |
| 999 | C | 5 | |a 10.1002/clc.23235 |9 -- missing cx lookup -- |1 K Ablefoni |p 873 - |2 Crossref |u Ablefoni K, Buchholz A, Ueberham L, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A (2019) Initial rivaroxaban dosing in patients with atrial fibrillation. Clin Cardiol 42(10):873–880 |t Clin Cardiol |v 42 |y 2019 |
| 999 | C | 5 | |a 10.1093/eurheartj/ehy802 |9 -- missing cx lookup -- |1 KL Wang |p 1492 - |2 Crossref |u Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP (2019) Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J 40(19):1492–1500 |t Eur Heart J |v 40 |y 2019 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.1161/JAHA.117.007633 |2 Crossref |u Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV et al (2018) Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 7(4) |
| 999 | C | 5 | |a 10.1093/ehjcvp/pvy041 |9 -- missing cx lookup -- |1 P Amarenco |p 70 - |2 Crossref |u Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ (2019) Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother 5(2):70–79 |t Eur Heart J Cardiovasc Pharmacother |v 5 |y 2019 |
| 999 | C | 5 | |1 S Hatano |y 1976 |2 Crossref |u Hatano S (1976) Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 54(5):541–553 |
| 999 | C | 5 | |a 10.1161/01.STR.20.7.864 |9 -- missing cx lookup -- |1 T Brott |p 864 - |2 Crossref |u Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V et al (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20(7):864–870 |t Stroke |v 20 |y 1989 |
| 999 | C | 5 | |a 10.1161/01.STR.19.5.604 |9 -- missing cx lookup -- |1 JC van Swieten |p 604 - |2 Crossref |u van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607 |t Stroke |v 19 |y 1988 |
| 999 | C | 5 | |2 Crossref |u Ingelheim B (2019) Fachinformation Pradaxa 150 mg Hartkapseln |
| 999 | C | 5 | |a 10.1016/S0140-6736(13)62343-0 |9 -- missing cx lookup -- |1 CT Ruff |p 955 - |2 Crossref |u Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962 |t Lancet |v 383 |y 2014 |
| 999 | C | 5 | |1 S Haas |y 2015 |2 Crossref |u Haas S (2015) im Namen des G-AFSC: [GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany]. Dtsch Med Wochenschr 140(Suppl 1):S13-14 |
| 999 | C | 5 | |a 10.1016/j.amjmed.2015.07.013 |9 -- missing cx lookup -- |1 MV Huisman |p 1306 - |2 Crossref |u Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K, Elsaesser A et al (2015) Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry Phase II. Am J Med 128(12):1306-1313.e1301 |t Am J Med |v 128 |y 2015 |
| 999 | C | 5 | |a 10.1016/j.joa.2016.11.003 |9 -- missing cx lookup -- |1 Y Okumura |p 289 - |2 Crossref |u Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Hanada S, Nomoto K et al (2017) Current use of direct oral anticoagulants for atrial fibrillation in Japan: findings from the SAKURA AF Registry. J Arrhythm 33(4):289–296 |t J Arrhythm |v 33 |y 2017 |
| 999 | C | 5 | |a 10.1586/erc.11.21 |9 -- missing cx lookup -- |1 JS Paikin |p 279 - |2 Crossref |u Paikin JS, Haroun MJ, Eikelboom JW (2011) Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev Cardiovasc Ther 9(3):279–286 |t Expert Rev Cardiovasc Ther |v 9 |y 2011 |
| 999 | C | 5 | |a 10.1093/europace/euz032 |9 -- missing cx lookup -- |1 G Boriani |p 1013 - |2 Crossref |u Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L et al (2019) Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 21(7):1013–1022 |t Europace |v 21 |y 2019 |
| 999 | C | 5 | |a 10.1177/2396987318812644 |9 -- missing cx lookup -- |1 K Haas |p 181 - |2 Crossref |u Haas K, Purrucker JC, Rizos T, Heuschmann PU, Veltkamp R (2019) Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime). Eur Stroke J 4(2):181–188 |t Eur Stroke J |v 4 |y 2019 |
| 999 | C | 5 | |a 10.1007/s00415-020-09795-3 |9 -- missing cx lookup -- |1 S Stoll |p 2007 - |2 Crossref |u Stoll S, Macha K, Marsch A, Gerner ST, Siedler G, Fröhlich K, Volbers B, Strasser EF, Schwab S, Kallmünzer B (2020) Ischemic stroke and dose adjustment of oral factor Xa inhibitors in patients with atrial fibrillation. J Neurol 267(7):2007–2012 |t J Neurol |v 267 |y 2020 |
| 999 | C | 5 | |a 10.1093/europace/eux087 |9 -- missing cx lookup -- |1 S Hellwig |p 569 - |2 Crossref |u Hellwig S, Grittner U, Audebert H, Endres M, Haeusler KG (2018) Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. EP Europace 20(4):569–574 |t EP Europace |v 20 |y 2018 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::